A Pilot Trial of Interpersonal Psychotherapy for the Treatment of Depression in Patients With Prostate, Colorectal, Lung and Pancreatic Cancer
There is now overwhelming evidence documenting the efficacy of psychotherapy in the treatment of depression in the general population. Surprisingly, however, given the high prevalence of depression in cancer patients, there are very few studies on the efficacy of psychotherapy in this population. Published studies of psychotherapy in cancer patients generally include patients with high heterogeneity of psychiatric diagnosis and frequently include patients without a psychiatric diagnosis, with the aim of preventing the appearance of a psychiatric disorder. This heterogeneity complicates the interpretation of the efficacy and specificity of these interventions. Specifically, the efficacy of psychotherapy for major depression in patients with cancer is unknown.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated May 19, 2017 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- New York State Psychiatric Institute
- Interventions being studied
- Behavioral: Psychotherapy
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- A primary psychiatric diagnosis of Major Depressive Disorder as defined by DSM-IV
- Diagnosis of prostate, colorectal, lung or pancreatic cancer (stage 1-4)
- A score of 16 or above in the 17-item HAM-D (Hamilton depression scale)
- Male or female ages 18-75.
- Ability to give consent
- English and/ or Spanish Speaking
- Lifetime history of psychosis or bipolar disorder
- History of substance abuse or dependence in the three months prior to the study.
- Current suicide risk.
- Patients who have ever failed IPT in the context of cancer.
- Patients who are receiving effective medication for depression
- Patients with T3, T4 and THS abnormal values
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- New York State Psychiatric InstituteNew York, New York
Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 19, 2017. Always confirm current availability with the study team.